BioPharmSignal logoBioPharmSignal

Biotech News

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

Context Therapeutics (CNTX)Context TherapeuticsClinical readout

CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc.

Related news

CGEMCullinan Therapeutics, Inc.2026-10-08 11:00 EST

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

URGNUroGen Pharma2026-11-02 13:00 EST

UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

IMCRImmunocore Holdings plc2026-10-15 11:00 EST

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

KYMRKymera2026-10-28 20:01 EST

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

MGNXMacroGenics2026-10-15 20:05 EST

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

ELVNEnliven Therapeutics2026-10-14 20:30 EST

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

NRIXNurix Therapeutics2026-11-03 21:01 EST

Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272

FATEFate Therapeutics2026-10-26 11:00 EST

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

View all latest news

Context Therapeutics

Solid-Tumor T-Cell Engagers Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors. CTIM-76 CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen. CT-95 CT-95 is a...

Recent company news

CNTXContext Therapeutics2026-09-09 11:30 EST

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

CNTXContext Therapeutics2026-08-05 20:15 EST

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

CNTXContext Therapeutics2026-07-10 20:05 EST

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CNTXContext Therapeutics2026-07-06 20:07 EST

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

CNTXContext Therapeutics2026-06-15 10:30 EST

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

Stock data

Close
0.19 USD
Market cap
222.35M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States